Characteristic features of primary testicular lymphoma and survival trends: a multicenter clinical study.

Clicks: 91
ID: 276842
2022
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
To retrospectively investigate the clinical characteristics, prognosis, treatment, and therapy outcome of Chinese patients with primary testicular lymphoma (PTL).we collected data of 49 PTL patients from four hospitals over 13 years. The median age was 63 years old. We described the clinical characteristics of the patients including the laterality, serum lactate dehydrogenase (LDH), pathology classification, stage, International prognostic index (IPI) scores and more.Complete remission (CR) was achieved in 34 patients and partial remission (PR) in 3 patients; Progressive disease (PD) was detected in 11 patients, and 10 patients died. The average progression-free survival (PFS) of all patients was 43.92 months, and the average overall survival (OS) was 47.55 months. The Ann Arbor stage, IPI score, and LDH were associated with OS, while Ann Arbor stage, IPI score, LDH, and histotype were significantly associated with PFS. Chemotherapy and radiotherapy following orchiectomy was associated with a significantly longer PFS.Most patients can achieve CR after induced therapy or orchiectomy. However, there are many associated prognostic factors.
Reference Key
sun2022characteristichematology Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sun, Yujiao;Yan, Xueshen;Zhao, Hongguo;Cui, Zhongguang;Wang, Yayun;Sun, Shuxiang;Ning, Xiaohan;Xu, Hong;
Journal Hematology (Amsterdam, Netherlands)
Year 2022
DOI
10.1080/16078454.2022.2119345
URL
Keywords
treatment survival analysis outcomes rituximab prognostic factors primary testicular lymphoma chemotheraphy orchiectomy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.